NASDAQ:EDBL

Edible Garden AG (NASDAQ:EDBL) Reports Strong Q2 Revenue Growth Despite Profitability Challenges

Font: Financial Modeling Prep  • Aug 14, 2026

Market Chart
  • Edible Garden AG Incorporated (NASDAQ:EDBL) reported strong Q2 revenue of $3.60 million, surpassing analyst estimates.
  • The company secured a significant distribution program with Target (NYSE: TGT) for its fresh-cut herbs, supporting scalable growth.
  • Despite robust revenue growth, Edible Garden AG remains unprofitable, with an earnings per share (EPS) of -$18.79 and a negative price-to-earnings (P/E) ratio.

Edible Garden AG Incorporated (NASDAQ:EDBL) is a company that grows fresh herbs and produce using Controlled Environment Agriculture (CEA). This method allows for year-round farming inside greenhouses. The CEA industry is currently consolidating, meaning fewer, larger companies are emerging, which increases demand for reliable suppliers like Edible Garden AG from national and regional retailers.

On August 14, 2026, Edible Garden AG reported its second-quarter financial results. The company announced revenue of $3.60 million, which was higher than the analyst estimate of $3.38 million. This positive result reflects a 12.80% increase in revenue compared to the same period last year.

The revenue growth is driven by strong demand for the company's cut herbs and other product offerings. As highlighted by GlobeNewswire, Edible Garden AG recently won a major distribution program with Target (NYSE: TGT) for its fresh-cut herbs in the Midwest. This expansion with a key retailer supports the company's strategy for scalable growth.

Despite the strong revenue, the company is not yet profitable. Edible Garden AG reported an earnings per share (EPS) of -$18.79. This figure, which shows the company's profit per share of stock, missed the analyst consensus estimate of -$11.70. A negative EPS indicates that the company had a net loss for the quarter.

This lack of profitability is also seen in other financial metrics. The company has a negative price-to-earnings (P/E) ratio of -0.02 and a negative operating cash flow. However, its balance sheet shows a debt-to-equity ratio of 0.38, which measures how much debt the company uses to finance its assets.

Market Overview
MDXH
MDxHealth S.A.
$0.81
74.89%
SURG
SurgePays, Inc.
$0.28
14.36%
VBIO
Valion Bio, Inc.
$0.19
11.59%
NU
Nu Holdings Ltd.
$15.23
9.33%
TSLL
Direxion Daily TSLA Bull 2X ETF
$8.76
1.39%
OTLK
Outlook Therapeutics, Inc.
$0.76
-14.90%
ONDS
Ondas Holdings Inc.
$9.24
3.70%
SPCX
Space Exploration Technologies Corp.
$140.00
-0.91%
INTC
Intel Corp.
$102.50
-1.97%
ONFO
Onfolio Holdings, Inc.
$2.59
12.12%